Pimavanserin Tartrate
1 NDC across 1 manufacturer|0 Generic,1 Brand
Pimavanserin Tartrate is used to treat hallucinations and parkinson disease, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Apr 29, 2016, and the first generic was approved Jan 16, 2024. In 2024, Medicare Part D spent $658 million on Pimavanserin Tartrate across 143,000 claims for 17,000 beneficiaries.
Pimavanserin Tartrate is available as 1 NDC from 1 manufacturer (0 generic, 1 brand), with NADAC prices from $170.50 to $170.50 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
1
0G / 1B
Manufacturers
1
competing in market
Price Spread
$170.50 – $170.50
per EA
7d Activity
avg +0.0% WoW · of 1 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
1 manufacturer producing PIMAVANSERIN TARTRATE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
NUPLAZID 34 MG CAPSULE | $170.4960 per EA | — |
Frequently Asked Questions
What is Pimavanserin Tartrate used to treat?
Pimavanserin Tartrate is used to treat hallucinations and parkinson disease, per the National Library of Medicine's MED-RT classification.
When did Pimavanserin Tartrate become available as a generic?
FDA approved the first generic Pimavanserin Tartrate (ANDA) on Jan 16, 2024.
How much does Medicare spend on Pimavanserin Tartrate?
In 2024, Medicare Part D spent $658 million on Pimavanserin Tartrate across 143,000 claims for 17,000 beneficiaries.
How many Pimavanserin Tartrate products are on the market?
The Pimavanserin Tartrate drug market contains 1 NDC from 1 manufacturer — 0 generic and 1 brand product.
What is the price range for Pimavanserin Tartrate?
NADAC reference prices for Pimavanserin Tartrate range from $170.4960 to $170.4960 per EA.
Which manufacturers make Pimavanserin Tartrate?
1 manufacturer lists Pimavanserin Tartrate in NADAC. Ranked by number of NDCs, the largest are Acadia Pharmaceuticals Inc. (1).